[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"severe-hemophilia-a-without-inhibitor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:severe-hemophilia-a-without-inhibitor":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100514651","a-study-on-the-bone-health-effectiveness-of-applying-recombinant-factor-viii-fc-rfviiifc-to-patients-with-hemophilia-a-prototype-a-100514651",false,"NCT05981274","A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)","A Prospective and Retrospective Interventional Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)","Inclusion Criteria:\n\n1. Patients with severe hemophilia A (all ages).\n2. Patients with moderate type hemophilia A with hemophilic arthropathy.\n3. Currently on rFVIIIFc regular prophylaxis and have previous medical record with regular prophylaxis with standard half-life product for one year\n4. Able and willing to undergo joint and bone examinations\n\nExclusion Criteria:\n\n1. Participants of other interventional studies.\n2. Patients with current inhibitors.\n3. History of major neurological disease (eg. Stroke, Parkinson's disease, neuropathy, etc.)\n4. History of major psychiatric disease (eg. Schizophrenia, bipolar disorder)\n5. Significantly impaired vision\u002Fhearing",true,"MALE",{"count":19,"type":20},45,"ESTIMATED","OBSERVATIONAL","Study Objectives\\*\n\n1. Provide a systematic evaluation of the treatment outcomes in patients with hemophilia A\n2. Emphasize the importance and clinical benefits of rFVIII-Fc in joint and bone health.\n3. Compare the clinical outcomes from 1 year before and after switching to EHL.\n4. Exploratory: Identify biomarkers that could provide more useful and convenient evaluations of joint and bone health. (Time-saving and easy to monitor)",[24],"Severe Hemophilia A Without Inhibitor","RECRUITING","2024-04-08",{"date":28,"type":29},"2024-04-10","ACTUAL",{"date":31,"type":29},"2023-07-14",{"date":33,"type":20},"2027-12-31",{"name":35,"class":36},"Tri-Service General Hospital","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":45,"minAge":4,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":37},"100500944","dynamics-of-the-anti-factor-viii-antibody-signature-during-treatment-with-emicizumab-100500944","NCT05802836","Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab","NAVIGATE","Inclusion Criteria:\n\n* Severe congenital hemophilia A (CHA)\n* Treatment with emicizumab irrespective of any other treatment\n* Informed consent\n\nExclusion Criteria:\n\n* No therapy with emicizumab\n* Immunosuppressive therapy\n* HIV-infection with CD4 (cluster of differentiation 4) cells \\\u003C200\u002Fµl","ALL",{"count":47,"type":20},100,"The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.",[50,51,24],"Severe Hemophilia A","Severe Hemophilia A With Inhibitor","2023-07-07",{"date":54,"type":29},"2023-07-10",{"date":56,"type":29},"2023-04-26",{"date":58,"type":20},"2029-12",{"name":60,"class":36},"Christoph Königs"]